Otter Capital
VC Fund
Palo Alto, United States
Otter Capital is a VC fund in Palo Alto focused on Agriculture and Biotechnology. Otter Capital makes equity investments in outstanding businesses. These are businesses that in Otter Capital’s judgment have good growth prospects, substantial competitive advantages and barriers to entry, and the ability now or in the future to generate significant cash returns on the capital deployed in the business.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries Otter Capital invests in
AgricultureBiotechnologyFarmingFinanceManufacturing
Stages Otter Capital invests in
Funding RoundSeries BSeries CSeries DSeries A
Countries Otter Capital invests in
United StatesChileBermuda
Round sizes
Series B $5M–$15MSeries C $5M–$30M
Round size
- Series B
- $5M–$15M
- Series C
- $5M–$30M
Investment Focus
Industry
- Agriculture 5 (25%)
- Biotechnology 5 (25%)
- Farming 2 (10%)
- Finance 2 (10%)
- Manufacturing 2 (10%)
Stage
- Funding Round 4 (20%)
- Series B 3 (15%)
- Series C 3 (15%)
- Series D 2 (10%)
- Series A 1 (5%)
Country
- United States 6 (30%)
- Chile 1 (5%)
- Bermuda 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BioConsortia
|
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity hashindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as commercial seed treatment, drench or granule products. We have a pipeline of products for increased fertilizer utilization, growth improvement and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression. | $15M / Venture - Series Unknown / Aug 01, 2025 | |
|
BioConsortia
|
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity hashindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as commercial seed treatment, drench or granule products. We have a pipeline of products for increased fertilizer utilization, growth improvement and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression. | $15M / Series F / Apr 01, 2024 | |
NewLeaf Symbiotics
|
NewLeaf Symbiotics develops and commercializes the bacteria found in Pink Pigmented Facultative Methylotrophs. NewLeaf Symbiotics has also filed its own related patents and is actively developing new technologies related to PPFMs. It is engaged in laboratory, greenhouse, and field product trials and expects to commercialize and license productsbeginning in 2014. | $45M / Series D / Dec 19, 2023 | |
|
BioConsortia
|
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity hashindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as commercial seed treatment, drench or granule products. We have a pipeline of products for increased fertilizer utilization, growth improvement and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression. | $15M / Apr 18, 2023 | |
|
BioConsortia
|
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity hashindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as commercial seed treatment, drench or granule products. We have a pipeline of products for increased fertilizer utilization, growth improvement and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression. | $15M / Series E / Apr 18, 2023 | |
Botanical Solutions
|
Botanical Solutions is a startup company that manufactures plant-based active ingredients and products from advanced botanicals. The company is the producer of biopesticide intended to assist in sustainable agriculture. The company's biopesticide assists in protecting crops against Botrytis effectively with no residues while taking care offield workers' safety, enabling growers to implement integrated pest management programs and meeting final customer's demands for quality and healthy food. | $6.1M / Series A / Jan 17, 2022 | |
|
NewLeaf Symbiotics
|
NewLeaf Symbiotics develops and commercializes the bacteria found in Pink Pigmented Facultative Methylotrophs. NewLeaf Symbiotics has also filed its own related patents and is actively developing new technologies related to PPFMs. It is engaged in laboratory, greenhouse, and field product trials and expects to commercialize and license productsbeginning in 2014. | $20M / Series D / Feb 24, 2020 | |
|
BioConsortia
|
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity hashindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as commercial seed treatment, drench or granule products. We have a pipeline of products for increased fertilizer utilization, growth improvement and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression. | $10M / Series D / Mar 14, 2018 | |
GLMX
|
The GLMX Trading Platform offers a single, integrated Money Market trading solution designed for the specific needs of institutional investors, funding managers and broker-dealers. Utilizing GLMX proprietary technology, the intuitive, browser-based interface achieves unprecedented market transparency and real-time efficiency. | $20M / Jan 25, 2018 | |
|
NewLeaf Symbiotics
|
NewLeaf Symbiotics develops and commercializes the bacteria found in Pink Pigmented Facultative Methylotrophs. NewLeaf Symbiotics has also filed its own related patents and is actively developing new technologies related to PPFMs. It is engaged in laboratory, greenhouse, and field product trials and expects to commercialize and license productsbeginning in 2014. | $30M / Series C / Jul 10, 2017 | |
| See all 20 investments → | |||
Co-Investors
Leaps by Bayer
3 deals together
RockPort Capital
3 deals together
S2G Investments
3 deals together
Swiss Re
2 deals together
Arthur Rock & Associates
1 deal together
BA Venture Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FinTech Investors
43,106 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Finance Investors
15,513 investors
Agriculture (agtech) Investors
10,346 investors
FinTech VC Funds
28,664 investors
Climate VC Funds
33,091 investors
FAQ
What does Otter Capital invest in?
Otter Capital invests primarily in Agriculture, Biotechnology and Farming startups, most often at Funding Round and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Otter Capital's check size?
Otter Capital typically joins rounds of $5M–$15M at Series B and $5M–$30M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Otter Capital participates in.
When did Otter Capital last invest?
The most recent investment recorded for Otter Capital closed in Aug 2025. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
